ALN-RSV01: Final Phase II data

Alnylam previously reported that ALN-RSV01 was well tolerated and reduced infection rate by 38% vs. placebo (see BioCentury, Jan. 28, 2008, & March 3, 2008). Cubist and Alnylam partnered to co-develop...